2Rustin GJ,Quinn M,Thigpen T,et al.Re:new guidelines to evaluatethe response to treatment in solid tumors(ovarian cancer).J Natl Cancer Inst,2004,96:487-488.
3Vergote I,Rustin GJ,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors(ovarian cancer)gynecologic cancer intergroup.J Natl Cancer Inst,2000,92:1 534-1 535.
4Coenen M,Berteloot P,Amant F,et al.Gemcitabine in Platin-paclitaxel resistant ovarian carcinoma.Proe Annu Meet Am Soc Clin Oncol,2000,19:A1 603-A1 615.
5Pfisterer J,Plante M,Vergote I,et al.Geneitabine/earboplatin(GC) VS earboplatin(C)in plantinum sensitive recurrent ovarian cancer (OVCA):results of a gynecologic cancer intergroup randomized phase 111 trial of the AGO OVAR.the NCIC CTG and the EORTCGCG.Proc Am Soc Clin Oncol,2004,449-5 005.
6Moufarij MA,Phillips DR,Cullinane C.Gemcitabine potentiates cisplatin eytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.Mol Pharmacol,2003,63:862-869.
